Alluvi, previously BI 4744, represents a significant breakthrough in obesity care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/